At a glance
ClinicalIndex Comparison Record- ✓Histologically proven clear cell renal carcinoma
- ✓Metastatic disease with clinical presentation consistent with metastatic renal carcinoma
- ✓Bidimensionally measurable disease by conventional imaging (radiography, ultrasound, CT, or other anatomic imaging)
- ✓Age ≥18 years
- ✕Significant prior radiotherapy >30 Gy to entire pelvis and/or lumbosacral spine
- ✕Clinically significant cardiac disease (NYHA Class III/IV)
- ✕Serious infection requiring antibiotic treatment or other serious illness
- ✕Chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to study agent administration
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Chimeric Monoclonal Antibody cG250 (^90Y-DOTA-cG250) in Patients With Advanced Renal Cancer
In Brief
A Phase 1 clinical trial evaluating Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250) for Renal Cell Carcinoma and 3 related conditions. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This was a Phase 1, open-label, dose-escalation study of yttrium-90 conjugated chimeric G250 (\^90Y-DOTA-cG250) in patients with advanced, measurable clear cell renal cell carcinoma (RCC). Study objectives were to determine the safety, targeting, and dosimetry of \^90Y-DOTA-cG250, using indium-111 conjugated chimeric G250 (\^111In-DOTA-cG250) as a surrogate, as well as to evaluate the immunogenicity of cG250.
Study Details
Timeline
Interventions
Patients received a single infusion of \^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.